Gilead Sciences begins phase III trial of leukaemia drug Zenopa The first patient has been dosed as part of Study 116, a trial that will assess the safety and efficacy of the drug in combination with rituximab among 160 subjects across Europe and the US. It is the first of several planned phase III trials exploring ... |
